Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab.

American journal of blood research Pub Date : 2021-10-15 eCollection Date: 2021-01-01
Sachin Punatar, Anant Gokarn, Lingaraj Nayak, Avinash Bonda, Akanksha Chichra, Sumeet Mirgh, Bhausaheb Bagal, Prashant Tembhare, Papagudi Subramanian, Navin Khattry
{"title":"Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab.","authors":"Sachin Punatar,&nbsp;Anant Gokarn,&nbsp;Lingaraj Nayak,&nbsp;Avinash Bonda,&nbsp;Akanksha Chichra,&nbsp;Sumeet Mirgh,&nbsp;Bhausaheb Bagal,&nbsp;Prashant Tembhare,&nbsp;Papagudi Subramanian,&nbsp;Navin Khattry","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The prognosis of patients with relapsed Early Thymic Precursor acute lymphoblastic leukemia (ETP-ALL) remains poor. Unlike B cell Precursor-ALL (BCP-ALL), there are no approved targeted therapies for ETP-ALL. Recent studies have identified a consistent expression of CD38 on the blasts of patients with T-ALL (both ETP-ALL and non ETP-ALL). Pre-clinical studies indicate that CD38 expression persists on the blasts of T-ALL even after receipt of conventional chemotherapy. These findings make CD38 an attractive targetable surface protein for patients with relapsed refractory T-ALL. We were the first to describe the clinical use of daratumumab in a patient of ETP-ALL, with relapsed disease post allogeneic transplant. We describe here the long term outcome of this patient more than 3 years after starting single agent daratumumab.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 5","pages":"528-533"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610796/pdf/ajbr0011-0528.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of blood research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The prognosis of patients with relapsed Early Thymic Precursor acute lymphoblastic leukemia (ETP-ALL) remains poor. Unlike B cell Precursor-ALL (BCP-ALL), there are no approved targeted therapies for ETP-ALL. Recent studies have identified a consistent expression of CD38 on the blasts of patients with T-ALL (both ETP-ALL and non ETP-ALL). Pre-clinical studies indicate that CD38 expression persists on the blasts of T-ALL even after receipt of conventional chemotherapy. These findings make CD38 an attractive targetable surface protein for patients with relapsed refractory T-ALL. We were the first to describe the clinical use of daratumumab in a patient of ETP-ALL, with relapsed disease post allogeneic transplant. We describe here the long term outcome of this patient more than 3 years after starting single agent daratumumab.

Abstract Image

Abstract Image

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用达拉单抗治疗复发的难治性早期胸腺前体急性淋巴细胞白血病患者的长期预后
早期胸腺前体急性淋巴细胞白血病(ETP-ALL)复发患者的预后仍然很差。与B细胞前体all (BCP-ALL)不同,ETP-ALL还没有被批准的靶向治疗方法。最近的研究发现CD38在T-ALL(包括ETP-ALL和非ETP-ALL)患者的细胞中一致表达。临床前研究表明,即使在接受常规化疗后,T-ALL细胞的CD38表达仍然存在。这些发现使CD38成为复发性难治性T-ALL患者的一个有吸引力的靶向表面蛋白。我们首次描述了在异基因移植后疾病复发的ETP-ALL患者中使用达拉单抗的临床应用。我们在这里描述了该患者在单药达拉单抗开始治疗3年以上的长期结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American journal of blood research
American journal of blood research MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
0.00%
发文量
14
期刊最新文献
The functional connotations of iron deficiency-effect on neutrophil oxidative burst activity in preschool children. Heparin-induced thrombocytopenia-II in hospitalized patients with surgery or deep vein thrombosis. Synonymous variant of TLR7 at restriction site rs864058 identified in Covid 19 Pakistani patients. Higher post procedural bleeding in patients with advanced chronic kidney disease undergoing percutaneous coronary intervention. A comprehensive review of the ten main platelet receptors involved in platelet activity and cardiovascular disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1